S-1/A: Applied DNA Sciences Eyes $7.1 Million Capital Infusion Through Share and Warrant Offering

Applied DNA Sciences aims to raise capital to further develop its Therapeutic DNA Production and MDx Testing Services through a public offering of common stock, warrants, and pre-funded warrants.

Summary

• Applied DNA Sciences is undertaking a public offering to sell up to 2,597,402 shares of common stock, Series A warrants, and Series B warrants, or alternatively, pre-funded warrants with accompanying Series A and B warrants.
• The assumed combined public offering price is $3.08 per share and warrants, based on the last reported sale price on May 13, 2024.
• The company intends to use the net proceeds of approximately $7.1 million for the further development of its Therapeutic DNA Production and MDx Testing Services, as well as for general corporate purposes.
• The Series A warrants are exercisable upon issuance at a price of $ per share and expire five years from the issuance date, while the Series B warrants are exercisable upon issuance at a price of $ per share and expire one year from the issuance date.
• The offering is expected to terminate on June 30, 2024, and there is no minimum number of securities or minimum aggregate amount of proceeds that is a condition of the closing of this offering.
• The company has engaged Craig-Hallum Capital Group LLC and Laidlaw & Company (UK) Ltd. as exclusive placement agents for the offering, who will receive a cash fee equal to 7.0% of the gross proceeds and warrants to purchase 5.0% of the offered shares.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the capital raise could benefit the company, the risks associated with the company's financial condition and the uncertainties of the market temper the outlook.

Positives

• The offering aims to provide capital for the development of Therapeutic DNA Production and MDx Testing Services, potentially driving future growth.
• The company has flexibility in offering common stock or pre-funded warrants to accommodate investor preferences.
• The engagement of experienced placement agents, Craig-Hallum and Laidlaw, could facilitate a successful offering.

Negatives

• The company has a history of net losses and there is substantial doubt about its ability to continue as a going concern.
• The offering is on a best-efforts basis, with no guarantee of raising the full $7.1 million.
• Existing stockholders will experience dilution as a result of the offering.
• There is no established public trading market for the Series Warrants or the pre-funded warrants, and the company does not expect a market to develop.

Risks

• The company's ability to continue as a going concern is uncertain.
• The market price of the common stock may be adversely impacted by the reverse stock split.
• The company may not raise the amount of capital it believes is required for its business plans.
• The company is subject to risks related to manufacturing, development, and industries, including potential FDA regulation of LDTs.

Future Outlook

The company plans to capitalize on the rapid growth of mRNA therapies and secure commercial-scale supply contracts for Linea DNA IVT templates and Linea RNAP.

Industry Context

The company is positioning itself to capitalize on the growing market for mRNA therapies and nucleic acid-based therapeutics, where DNA is a critical starting material.

Comparison to Industry Standards

• The document mentions that as of the first quarter of calendar year 2024, there were 4,002 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use DNA in their manufacturing process.
• The document mentions that as of the 1st quarter of calendar 2024, there were approximately 450 mRNA therapies under development, with the large majority of these therapies (67%) in the preclinical stage.
• The document does not provide a direct comparison to industry standards, but it highlights the advantages of the Linea DNA platform over legacy plasmid-based DNA manufacturing technologies.
• The document does not provide a direct comparison to industry standards, but it highlights the advantages of the Linea IVT platform over conventional mRNA production.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's ability to fund its operations and execute its business plan will be enhanced by the capital raise.
• The company's stakeholders will benefit from the development of Therapeutic DNA Production and MDx Testing Services.

Next Steps

• The company will file the Final Prospectus with the Commission.
• The company will seek to obtain the Required Approvals.
• The company will work with the Co-Placement Agents to solicit offers to purchase the Securities.

Key Dates

Keywords

common stock, warrants, pre-funded warrants, public offering, Therapeutic DNA Production, MDx Testing Services, capital raise, biotechnology, APDN, Applied DNA Sciences